The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Increased neutrophil infiltration and lower prevalence of tumor mutation burden and microsatellite instability are hallmarks of RAS mutant colorectal cancers.
 
Emil Lou
Honoraria - Boston Scientific; Daiichi Sankyo/UCB Japan (Inst); GlaxoSmithKline; Novocure
Consulting or Advisory Role - Boston Scientific; Novocure; Novocure; Novocure; Novocure
Research Funding - Novocure
Travel, Accommodations, Expenses - GlaxoSmithKline
(OPTIONAL) Uncompensated Relationships - Caris Life Sciences; Minnetronix Medical; NomoCan
 
Yasmine Baca
No Relationships to Disclose
 
Joanne Xiu
Employment - Caris Life Sciences
 
Andrew Nelson
No Relationships to Disclose
 
Subbaya Subramanian
No Relationships to Disclose
 
Mohamed E. Salem
Consulting or Advisory Role - Bristol-Myers Squibb; Exelixis; Taiho Pharmaceutical
Speakers' Bureau - Genentech/Roche; Taiho Pharmaceutical
 
Muhammad Shaalan Beg
Consulting or Advisory Role - Array BioPharma; AstraZeneca/MedImmune; Cancer Commons; Ipsen; Legend Biotech
Research Funding - Agios (Inst); ArQule (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); CASI Pharmaceuticals (Inst); Celgene (Inst); Five Prime Therapeutics (Inst); Genentech (Inst); ImmuneSensor Therapeutics (Inst); MedImmune (Inst); Merck Serono (Inst); Sillajen (Inst); Tolero Pharmaceuticals (Inst)
 
Elisa Fontana
Employment - HCA/Sarah Cannon
Consulting or Advisory Role - Astellas Pharma (I); Bristol-Myers Squibb (I); Celgene (I); SERVIER (I)
Patents, Royalties, Other Intellectual Property - Patent No: 1716712.3 pending (I)
Travel, Accommodations, Expenses - Bristol-Myers Squibb (I); SERVIER (I)
 
Maria Diab
No Relationships to Disclose
 
Philip Agop Philip
Honoraria - Array BioPharma; AstraZeneca; Bayer; Blueprint Medicines; Celgene; Ipsen; Merck; SynCoreBio; TriSalus Life Sciences
Consulting or Advisory Role - Celgene; Daiichi Sankyo; Ipsen; Merck; SynCoreBio; Taiho Pharmaceutical; TriSalus Life Sciences
Speakers' Bureau - Bayer; Celgene; Incyte; Ipsen; Novartis
Research Funding - Advanced Accelerator Applications (Inst); ASLAN Pharmaceuticals (Inst); Bayer (Inst); boston biomedical (Inst); Caris Life Sciences (Inst); Caris Life Sciences (Inst); Genentech (Inst); halozyme (Inst); Immunomedics (Inst); incyte (Inst); incyte (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Merck (Inst); merus (Inst); Momenta Pharmaceuticals (Inst); novartis (Inst); Plexxikon (Inst); QED Therapeutics (Inst); QED Therapeutics (Inst); Regeneron (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); TYME (Inst); tyme (Inst)
Travel, Accommodations, Expenses - Abbvie; celgene; Rafael Pharmaceuticals
(OPTIONAL) Uncompensated Relationships - Caris MPI; Rafael Pharmaceuticals
 
Richard M. Goldberg
Stock and Other Ownership Interests - Advanced Chemotherapy Technologies
Honoraria - Amgen
Consulting or Advisory Role - AstraZeneca; Bayer; Merck; Novartis; Taiho Pharmaceutical
Expert Testimony - Genentech/Roche; Taiho Pharmaceutical
Travel, Accommodations, Expenses - Amgen; Merck; Merck KGaA
 
Ritu Pandey
No Relationships to Disclose
 
Tobias Arkenau
No Relationships to Disclose
 
Weijing Sun
Honoraria - Genentech/Roche; Taiho Pharmaceutical
Consulting or Advisory Role - Bayer
Research Funding - Bayer; Merck (Inst)
 
Heinz-Josef Lenz
Honoraria - Bayer; Boehringer Ingelheim; GlaxoSmithKline; Isofol Medical; Merck Serono; Roche
Consulting or Advisory Role - Bayer; BMS; GlaxoSmithKline; Merck Serono; Roche
Travel, Accommodations, Expenses - Bayer; Merck Serono
 
Anthony Frank Shields
Consulting or Advisory Role - Caris Life Sciences; ImaginAb
Speakers' Bureau - Caris Life Sciences
Research Funding - Alkermes; Astellas Pharma; AstraZeneca; Bayer; Boehringer Ingelheim; Boston Biomedical; Caris Life Sciences; Daiichi Sankyo; Eisai; Esperas Pharma; Esperas Pharma; Exelixis; Five Prime Therapeutics; H3 Biomedicine; Halozyme; Hutchison China Meditech; ImaginAb; Incyte; Inovio Pharmaceuticals; Jiangsu Alphamab Biopharmaceuticals; Lexicon; LSK BioPharma; MSK Pharma; Nouscom; Plexxikon; Repertoire Immune Medicines; Seagen; Shanghai HaiHe Pharmaceutical; Taiho Pharmaceutical; Telix Pharmaceuticals; Xencor
Travel, Accommodations, Expenses - Caris Life Sciences; GE Healthcare; ImaginAb; Inovio Pharmaceuticals; TransTarget
 
Wafik S. El-Deiry
Stock and Other Ownership Interests - Oncoceutics; p53-Therapeutics
Consulting or Advisory Role - Boehringer Ingelheim
Research Funding - Bayer; D&D Pharmatech; D&D Pharmatech; D&D Pharmatech; Loxo; Morphotek; Tarmeta Biosciences
Patents, Royalties, Other Intellectual Property - Patent on TIC10 (ONC201); Patents pending on the use of small molecules to target mutant p53
Other Relationship - Caris Life Sciences
 
Wolfgang Michael Korn
Employment - Caris Life Sciences
Leadership - Caris Life Sciences
Consulting or Advisory Role - Merck Sharp & Dohme
Travel, Accommodations, Expenses - Merck Sharp & Dohme